Alunbrig 90 mg

ALUNBRIG 90 MG tablets contain brigatinib, a medication used to treat certain types of cancer. This oral medication is manufactured by Takeda Canada Inc. and is available in 7, 28, or 30 tablet packs.

ALUNBRIG 90 MG is primarily used in the treatment of non-small cell lung cancer (NSCLC). This medication targets specific genetic mutations to help manage cancer growth. Patients often wonder, 'What is brigatinib used for?' and the answer lies in its role as a targeted therapy for advanced NSCLC.

Common effects of ALUNBRIG 90 MG may include nausea, fatigue, and cough. Some users also report diarrhea and increased appetite. These effects can vary widely among individuals, and it's important to consult a healthcare provider for personalized advice.

ALUNBRIG 90 MG should be handled with care, stored at room temperature, and kept out of reach of children. Patients should follow their healthcare provider's instructions regarding administration and monitor for any adverse reactions. Always inform your healthcare provider about any pre-existing conditions before starting this medication.

ALUNBRIG 90 MG may interact with certain medications, including strong CYP3A inducers and inhibitors. It's important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare provider.